Semaglutide and mental side effects: what you need to weigh up

What the formal safety reviews actually found

When the MHRA and the European Medicines Agency reviewed GLP-1 receptor agonists, including semaglutide, for a possible link to suicidal ideation and self-harm, neither concluded that a causal relationship had been established. Large observational datasets (covering hundreds of thousands of patients) consistently showed no increase in depression or suicidality in people using these medicines compared with matched controls. That finding matters, because it means the picture from real-world use broadly aligns with the clinical trial data.

At the same time, the NHS medicines information for semaglutide does list mood changes and depression among side effects to be aware of, and the Patient Information Leaflet asks patients to contact their doctor or pharmacist if they experience any new or worsening depression, thoughts of self-harm, or changes in behaviour. That is not a signal that these effects are common — it is a standard safety precaution that reflects the uncertainty inherent in prescribing any medicine at population scale. The broader side-effect picture, including physical symptoms, is covered on our semaglutide side effects overview.

The honest position, then, is that formal evidence is reassuring at a group level, but it cannot tell you with certainty what your individual experience will be. That gap is exactly what a prescriber's assessment is for.

Mood changes people report, and what might explain them

A number of people do report changes in mood during treatment. Some describe increased anxiety in the early weeks, often during dose escalation. Others notice a flattening of enthusiasm (sometimes called "Wegovy mental side effects" in patient communities) particularly around food, which can bleed into reduced pleasure in social situations built around eating. This is distinct from clinical depression, but it is worth naming honestly.

There are plausible biological reasons for these experiences. Semaglutide acts on GLP-1 receptors found not just in the gut but in parts of the brain involved in reward and mood. Rapid changes in eating patterns, lower caloric intake and significant weight loss itself can all affect how someone feels day to day. Poor sleep, which sometimes accompanies early GI side effects, does not help either. If you want to understand the full range of mental health side effects of Wegovy, including which are most commonly reported and how they tend to unfold over time, our dedicated page covers the detail. The timing often matters: symptoms that surface in the first few weeks and settle as the body adjusts are a different concern from mood changes that persist or worsen at a stable dose.

For a fuller look at the experience of side effects across the treatment timeline, the worst side effects timeline page gives useful context about what tends to ease and when.

When you should get medical help

Some changes in mental wellbeing need prompt attention rather than a wait-and-see approach. Contact your GP or prescriber the same day if you notice thoughts of self-harm or suicide, a significant and rapid worsening of depression, agitation or aggression that feels out of character, or any hallucinations or paranoid thoughts. These are not described as common effects of semaglutide, but they are on the list of things to act on quickly rather than monitor at home.

Less urgent but still worth raising at your next review: persistent low mood lasting more than two weeks, anxiety that disrupts daily life, or a sense that your relationship with food has shifted in a way that concerns you. If you have a history of an eating disorder, this is particularly important to discuss with your prescriber before starting, our Wegovy overview page outlines the full prescribing context. The MHRA's Yellow Card scheme is also open to patients who want to report any suspected side effect directly to the regulator; those reports genuinely inform ongoing safety surveillance.

A question our prescribers hear regularly: "does this mean I shouldn't take it if I have depression?" The answer is not automatic disqualification. Pre-existing mental health conditions are part of the clinical picture a prescriber weighs, not an absolute barrier in every case. What matters is an honest conversation about your history, your current support, and how closely you can monitor your own wellbeing during the early months of treatment.

Making the decision with your prescriber, not around them

The mental side effects question is a good example of why semaglutide cannot sensibly be obtained without a clinical assessment. A prescriber who knows your mental health history, your current medicines (some antidepressants, for instance, interact with GLP-1 titration schedules in ways worth discussing), and your circumstances is far better placed to judge individual risk than any generic online resource.

It is also worth knowing that the Wegovy dental side effects page addresses another side-effect area patients often research before starting, dental health considerations during treatment are more common than people expect. For the wider side-effect landscape, our Wegovy side effects page brings together the full safety picture.

At nume, every consultation is read by a GPhC-registered Independent Prescriber, a named clinician, not an automated triage system. If you have questions about mental health and suitability before you decide, you might find it useful to look at our clinical team or review the frequently asked questions. When you are ready, speak to our prescribers as part of a free consultation; the conversation about your mental health history is part of the assessment, not an afterthought.